OPKO Health, Inc. Business Acquisition, Pro Forma Revenue
OPKO Health, Inc. (OPK) reported Business Acquisition, Pro Forma Revenue of $19.77 million for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-07.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2015-02-27
- OPKO Health, Inc. business acquisition, pro forma revenue for the quarter ending 2014-09-30 was $19.77M, a 4.21% decline year-over-year.
- OPKO Health, Inc. business acquisition, pro forma revenue for the quarter ending 2014-06-30 was $23.55M, a 1.16% decline year-over-year.
- OPKO Health, Inc. business acquisition, pro forma revenue for the quarter ending 2013-12-31 was $20.69M, a 27.19% increase year-over-year.
- OPKO Health, Inc. business acquisition, pro forma revenue for the quarter ending 2013-09-30 was $20.64M, a 47.69% increase year-over-year.
- OPKO Health, Inc. business acquisition, pro forma revenue for fiscal 2013 was $96.53M, a 80.11% increase from fiscal 2012.
- OPKO Health, Inc. business acquisition, pro forma revenue for fiscal 2012 was $53.59M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2014-09-30 | $19.77M 10-Q · filed 2014-11-07 | $43.32M derived: sum of 2 quarters · filed 2014-11-07 | $65.59M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $23.55M 10-Q · filed 2014-08-11 | $45.82M 10-Q · filed 2014-08-11 | ||
| 2013-12-31 | $20.69M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $41.33M derived: sum of 2 quarters · filed 2015-02-27 | $65.15M derived: sum of 3 quarters · filed 2015-02-27 | $96.53M 10-K · filed 2015-02-27 |
| 2013-09-30 | $20.64M 10-Q · filed 2014-11-07 | $44.46M derived: sum of 2 quarters · filed 2014-11-07 | $75.84M 10-Q · filed 2014-11-07 | $92.11M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | $23.82M 10-Q · filed 2014-08-11 | $55.20M 10-Q · filed 2014-08-11 | $71.47M derived: sum of 3 quarters · filed 2015-02-27 | $85.44M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $31.38M 10-Q · filed 2014-05-09 | $47.64M derived: sum of 2 quarters · filed 2015-02-27 | $61.62M derived: sum of 3 quarters · filed 2015-02-27 | |
| 2012-12-31 | $16.27M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $30.24M derived: sum of 2 quarters · filed 2015-02-27 | $53.59M 10-K · filed 2015-02-27 | |
| 2012-09-30 | $13.98M 10-Q · filed 2013-11-12 | $37.33M 10-Q · filed 2013-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |